Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 17, 2006

Lentigen Receives Grant to Evaluate the Use of Lentiviral-Engineered T Cells for Cancer Therapy

  • Lentigen obtained an NIH SBIR Phase I funding to evaluate the use of lentiviral-engineered T cells that express chimeric receptors and signaling modules to improve efficacy of cancer immunotherapies directed against the tumor-associated antigen, mesothelin.

    Mesothelin is a potentially promising target in mesothelioma, squamous cell cancers of the head and neck, and ovarian, cervical, esophageal, pancreatic, and many non-small-cell-lung cancers (NSCLC), according to Lentigen. The primary collaborator on this award is

    The ultimate goal for Lentigen and Carl H. June, M.D., of the University of Pennsylvania School of Medicine, primary collaborator on this award, will be to demonstrate that human T cells can be modified using a lentiviral delivery system to directly target cancers that express mesothelin.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »